RIMKLB and colorectal carcinoma: NUMBL, TSPAN11, PHF21A, PDGFRA, ZNF385A, and RIMKLB were selected as the lymphangiogenesis and immune-related signature that could be used for prognosis and prediction of therapeutic responses in CRC.